EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53

Kyung-Jun Lee, Nitya Singh, Michael Bizuneh, Nam-Hyeok Kim, Hyeong Su Kim iD, Youngmi Kim, Jae-Jun Lee, Jung Han Kim, Jiye Kim, Soo Young Jeong, Hye-Yon Cho iD, Sung Taek Park iD

Journal of Personalized Medicine · 25.08.2023 · 13 (9) · 1302

DOI: 10.3390/jpm13091302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 25.08.2023. Verfasst von Kyung-Jun Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of New Frontier Research Team, Hallym University, Chuncheon 24252, Republic of Korea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Health Industry Development Institute, Hallym University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

To examine miR-429-meditated DEAD (Asp-Glu-Ala-Asp) box polypeptide 53 (DDX53) function in endometrial cancer (EC). (2)

Methods

DDX53 and miR-429 levels were measured using quantitative real-time polymerase chain reaction and western blotting assays, cell invasion and migration using Transwell invasion and wound healing assays, and cell proliferation using colony-forming/proliferation assays. A murine xenograft model was also generated to examine miR-429 and DDX53 functions in vivo. (3)

Results

DDX53 overexpression (OE) promoted key cancer phenotypes (proliferation, migration, and invasion) in EC, while in vivo, DDX53 OE hindered tumor growth in the murine xenograft model. Moreover, miR-429 was identified as a novel miRNA-targeting DDX53, which suppressed EC proliferation and invasion. (4)

Conclusions

DDX53 and miR-429 regulatory mechanisms could provide novel molecular therapies for EC.

Schlagwörter

Stichwörter der Autor:innen

DDX53anti-cancer drug-resistanceendometrial cancermiR-429

Autor:innen und Institutionen

  • Institute of New Frontier Research Team, Hallym University, Chuncheon 24252, Republic of Korea.
  • Division of Hemato-Oncology, Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea.
  • Departments of Anesthesiology and Pain Medicine, Chuncheon Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea.
  • Department of Obstetrics and Gynecology, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea.
  • Department of Obstetrics and Gynecology, Dongtan Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Kyeonggido 18450, Republic of Korea.

ORCID-Profile: Hyeong Su Kim, Hye-Yon Cho, Sung Taek Park

Förderung

  • National Research Foundation of Korea
  • Korea Health Industry Development Institute
  • Hallym University
  • Ministry of Science and ICT (MSIT)
  • Ministry of Health and Welfare

Zitieren

APA

Lee, K. J., Singh, N., Bizuneh, M., Kim, N. H., Kim, H. S., Kim, Y., Lee, J. J., Kim, J. H., Kim, J., Jeong, S. Y., Cho, H. Y., & Park, S. T. (2023). miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53. Journal of Personalized Medicine, 13(9), 1302. https://doi.org/10.3390/jpm13091302

Vancouver

Lee KJ, Singh N, Bizuneh M, Kim NH, Kim HS, Kim Y, et al. miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53. Journal of Personalized Medicine. 2023;13(9):1302. doi:10.3390/jpm13091302

BibTeX
@article{Lee2023,
  author = {Lee, Kyung-Jun and Singh, Nitya and Bizuneh, Michael and Kim, Nam-Hyeok and Kim, Hyeong Su and Kim, Youngmi and Lee, Jae-Jun and Kim, Jung Han and Kim, Jiye and Jeong, Soo Young and Cho, Hye-Yon and Park, Sung Taek},
  title = {miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  volume = {13},
  number = {9},
  pages = {1302},
  doi = {10.3390/jpm13091302}
}
Kostenlos starten →